David Hallal's Insider Trades & SAST Disclosures
David Hallal's most recent trade in Scholar Rock Holding Corp was a trade of 275,167 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on May 2, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern David Hallal.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Scholar Rock Holding Corp | David L. Hallal | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 May 2025 | 275,167 | 275,167 | - | - | Stock Option (Right to Buy) | |
| Scholar Rock Holding Corp | David L. Hallal | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Apr 2025 | 1,250,000 | 1,804,095 (6%) | 4% | 0 | Common Stock | |
| Scholar Rock Holding Corp | David L. Hallal | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Apr 2025 | 250,000 | 554,095 (1%) | 0% | 0 | Common Stock | |
| Kalaris Therapeutics Inc. | David L. Hallal | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Apr 2025 | 18,000 | 18,000 | - | - | Stock Option (Right to Buy) | |
| Scholar Rock Holding Corp | David L. Hallal | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 18,000 | 18,000 | - | - | Stock Option (Right to Buy) | |
| Scholar Rock Holding Corp | David L. Hallal | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 13,500 | 304,095 (1%) | 0% | 0 | Common Stock | |
| Seer Inc - Ordinary Shares... | David L. Hallal | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2024 | 58,178 | 355,128 | - | 0 | Class A Common Stock | |
| ITeos Therapeutics Inc | David L. Hallal | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2024 | 24,200 | 24,200 | - | - | Stock Option (Right to Buy) | |
| Kalaris Therapeutics Inc. | David L. Hallal | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2024 | 35,000 | 2,143,662 | - | 0 | Common Stock | |
| Scholar Rock Holding Corp | David Hallal | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2023 | 36,000 | 36,000 | - | - | Stock Option (Right to Buy) | |
| ITeos Therapeutics Inc | David Hallal | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2023 | 22,383 | 22,383 | - | - | Stock Option (Right to Buy) | |
| Kalaris Therapeutics Inc. | David Hallal | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 May 2023 | 35,000 | 2,108,662 | - | 0 | Common Stock | |
| Kalaris Therapeutics Inc. | David Hallal | Director, Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 7.35 per share. | 29 Sep 2022 | 400,000 | 720,965 | - | 7.4 | 2,940,920 | Common Stock |
| Kalaris Therapeutics Inc. | David Hallal | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 4.61 per share. | 28 Jul 2022 | 3,253,796 | 16,674,766 | - | 4.6 | 15,000,000 | Common Stock |
| Kalaris Therapeutics Inc. | David Hallal | Director, Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 5.33 per share. | 21 Jul 2022 | 4,227 | 2,073,662 | - | 5.3 | 22,528 | Common Stock |
| Scholar Rock Holding Corp | David Hallal | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2022 | 14,000 | 14,000 | - | - | Stock Option (Right to Buy) | |
| Seer Inc - Ordinary Shares... | David Hallal | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2022 | 29,640 | 29,640 | - | - | Stock Option (right to buy) | |
| Seer Inc - Ordinary Shares... | David Hallal | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2022 | 9,945 | 273,507 | - | 0 | Class A Common Stock | |
| Kalaris Therapeutics Inc. | David Hallal | Director, Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 3.67 per share. | 03 Jun 2022 | 65,725 | 2,077,889 | - | 3.7 | 241,106 | Common Stock |
| Scholar Rock Holding Corp | David Hallal | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 May 2022 | 28,000 | 28,000 | - | - | Stock Option (Right to Buy) | |
| Kalaris Therapeutics Inc. | David Hallal | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 May 2022 | 27,500 | 27,500 | - | - | Stock Option (Right to Buy) | |
| Kalaris Therapeutics Inc. | David Hallal | Director, Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 5.87 per share. | 21 Apr 2022 | 4,227 | 2,143,614 | - | 5.9 | 24,812 | Common Stock |
| Kalaris Therapeutics Inc. | David Hallal | Director, Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 8.01 per share. | 24 Jan 2022 | 17,100 | 2,213,566 | - | 8.0 | 136,889 | Common Stock |
| ITeos Therapeutics Inc | David Hallal | Director | Sale of securities on an exchange or to another person at price $ 43.57 per share. | 20 Dec 2021 | 50,000 | 0 | - | 43.6 | 2,178,500 | Common Stock |
| ITeos Therapeutics Inc | David Hallal | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Dec 2021 | 30,000 | 37,039 | - | - | Stock Option (Right to Buy) | |
| ITeos Therapeutics Inc | David Hallal | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.95 per share. | 20 Dec 2021 | 30,000 | 50,000 | - | 3.0 | 88,500 | Common Stock |
| ITeos Therapeutics Inc | David Hallal | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.30 per share. | 20 Dec 2021 | 20,000 | 20,000 | - | 4.3 | 86,000 | Common Stock |
| ITeos Therapeutics Inc | David Hallal | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Dec 2021 | 20,000 | 114,682 | - | - | Stock Option (Right to Buy) | |
| ITeos Therapeutics Inc | David Hallal | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2021 | 16,608 | 16,608 | - | - | Stock Option (Right to Buy) | |
| Seer Inc - Ordinary Shares... | David Hallal | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2021 | 15,000 | 15,000 | - | - | Stock Option (right to buy) | |
| Scholar Rock Holding Corp | David Hallal | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 May 2021 | 7,800 | 7,800 | - | - | Stock Option (Right to Buy) | |
| Kalaris Therapeutics Inc. | David Hallal | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2021 | 22,500 | 22,500 | - | - | Stock Option (Right to Buy) | |
| Kalaris Therapeutics Inc. | David Hallal | Director, Chief Executive Officer, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jan 2021 | 273,000 | 273,000 | - | - | Stock Option (Right to Buy) | |
| Kalaris Therapeutics Inc. | David Hallal | Director, Chief Executive Officer, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jan 2021 | 147,000 | 2,230,666 | - | 0 | Common Stock | |
| Kalaris Therapeutics Inc. | David Hallal | Director, Chief Executive Officer, Ten Percent Owner | 03 Aug 2020 | 20,000,000 | 0 | - | - | Series A-2 Convertible Preferred Stock | ||
| Kalaris Therapeutics Inc. | David Hallal | Director, Chief Executive Officer, Ten Percent Owner | 03 Aug 2020 | 13,420,970 | 13,420,970 | - | - | Common Stock | ||
| Kalaris Therapeutics Inc. | David Hallal | Director, Chief Executive Officer, Ten Percent Owner | 03 Aug 2020 | 1,100,000 | 0 | - | - | Series A-4 Convertible Preferred Stock | ||
| Kalaris Therapeutics Inc. | David Hallal | Director, Chief Executive Officer, Ten Percent Owner | 03 Aug 2020 | 738,153 | 738,153 | - | - | Common Stock | ||
| Kalaris Therapeutics Inc. | David Hallal | Director, Chief Executive Officer, Ten Percent Owner | 03 Aug 2020 | 233,333 | 0 | - | - | Series A-4 Convertible Preferred Stock | ||
| Kalaris Therapeutics Inc. | David Hallal | Director, Chief Executive Officer, Ten Percent Owner | 03 Aug 2020 | 156,577 | 1,120,965 | - | - | Common Stock | ||
| Kalaris Therapeutics Inc. | David Hallal | Director, Chief Executive Officer, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jul 2020 | 1,101,000 | 1,101,000 | - | - | Stock Option (Right to Buy) | |
| ITeos Therapeutics Inc | David Hallal | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jul 2020 | 16,608 | 0 | - | - | Stock Option (Right to Buy) | |
| Scholar Rock Holding Corp | David Hallal | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2020 | 13,000 | 13,000 | - | - | Stock Option (right to buy) | |
| Scholar Rock Holding Corp | David Hallal | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2020 | 7,000 | 7,000 | - | - | Stock Option (right to buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges